Impressive growth rate at DanCann Pharma A/S
COPENHAGEN, Denmark, 15 June 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) hereby announce, that the development of the mother plant genetics in BIOTECH-PHARM1, the production facilities inaugurated in April, exceeds the Company’s expectations.In April, the Danish pharmaceutical manufacturer inaugurated its new production facilities BIOTECH-PHARM1 in Ansager and there is already plenty of activity in the Company's unique cultivation environment. The growth rate of the cannabis plants is high, while the consumption of fertilizers and nutrients is surprisingly low.